Oral Semaglutide 25mg Shows 16.6% Weight Loss in OASIS-4 Trial

With efficacy data from the OASIS-4 trial finally translated into a real-world product, Novo Nordisk’s oral semaglutide establishes a new benchmark for peptide oral delivery. The SNAC technology, which protects the molecule from gastric degradation, has proven capable of delivering weight loss approaching injectable levels. For biotech investors, the 16.6% absolute weight loss underscores the pill’s competitive edge in a crowded pipeline that includes Eli Lilly's orforglipron, and the one-in-three shot at 20%+ reduction keeps the high-efficacy bar high.

The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has approved an oral formulation of Novo Nordisk's blockbuster weight-loss drug Wegovy, triggering a surge in private demand as thousands seek easier access to semaglutide therapy. Unlike the existing weekly injection, the once-daily Wegovy Pill uses a proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) coating that allows the peptide to survive stomach acid and be absorbed through the gastric mucosa, a drug delivery innovation first validated with Rybelsus (oral semaglutide for type 2 diabetes). The approval, which came on 12 June 2026, immediately opened a new front in the UK's obesity crisis, with private providers including Boots, Superdrug, Morrisons, and numerous online pharmacies rushing to stock the tablets. Reports suggest private waiting lists have ballooned to nearly 100,000 individuals, underscoring the magnitude of demand that has outstripped supply of injectable GLP-1 therapies.

“

Notably, 87% of those adhering to treatment lost at least 5% of their starting weight—an outcome often cited as clinically meaningful—and roughly one in three shed 20% or more.

The clinical foundation rests on the OASIS-4 trial, a global study that enrolled adults with overweight or obesity. At 64 weeks, participants on a 25 mg daily dose of oral semaglutide achieved a mean weight reduction of 16.6% versus 2.7% in the placebo group. Notably, 87% of those adhering to treatment lost at least 5% of their starting weight—an outcome often cited as clinically meaningful—and roughly one in three shed 20% or more. While this efficacy is slightly below the up-to-20.7% average loss reported for injectable Wegovy, the oral route eliminates needle aversion and simplifies logistics, potentially expanding the addressable patient population significantly. The price point is expected to be lower than the injection, which may further accelerate uptake, though specific pricing has not been universally published.

From a market perspective, the move positions Novo Nordisk to capture a larger share of the $100 billion global weight-loss market. The company’s injectable semaglutide already dominates, but manufacturing constraints have limited supply. An oral version with potentially easier manufacturing and room-temperature storage (blister packs versus refrigerated pens) could ease some bottlenecks. However, the pill requires strict adherence to a fasting stomach protocol: patients must swallow it whole with no more than 120 ml of water and then wait 30 minutes before eating, drinking, or taking other medications. In contrast, the injection is not influenced by meals. This behavioral hurdle may impact real-world adherence rates, a factor that investors and prescribers will watch closely as the launch unfolds.